119 related articles for article (PubMed ID: 33367744)
1. Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.
Rossing P; Strand J; Avogaro A; Becka M; Kanefendt F; Otto C
Nephrol Dial Transplant; 2021 Dec; 36(12):2263-2273. PubMed ID: 33367744
[TBL] [Abstract][Full Text] [Related]
2. Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial.
Düngen HD; Kober L; Nodari S; Schou M; Otto C; Becka M; Kanefendt F; Winkelmann BR; Gislason G; Richard F; Nielsen OW; Gheorghiade M; Senni M
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):942-951. PubMed ID: 30452784
[TBL] [Abstract][Full Text] [Related]
3. Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.
Duengen HD; Kim RJ; Zahger D; Orvin K; Kornowski R; Admon D; Kettner J; Shimony A; Otto C; Becka M; Kanefendt F; Romo AI; Hasin T; Ostadal P; Rojas GC; Senni M;
Am Heart J; 2020 Jun; 224():129-137. PubMed ID: 32375104
[TBL] [Abstract][Full Text] [Related]
4. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
5. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
6. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE
Lancet Diabetes Endocrinol; 2018 Dec; 6(12):925-933. PubMed ID: 30413396
[TBL] [Abstract][Full Text] [Related]
8. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
Tuttle KR; Brosius FC; Adler SG; Kretzler M; Mehta RL; Tumlin JA; Tanaka Y; Haneda M; Liu J; Silk ME; Cardillo TE; Duffin KL; Haas JV; Macias WL; Nunes FP; Janes JM
Nephrol Dial Transplant; 2018 Nov; 33(11):1950-1959. PubMed ID: 29481660
[TBL] [Abstract][Full Text] [Related]
9. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Hanrahan JP; de Boer IH; Bakris GL; Wilson PJ; Wakefield JD; Seferovic JP; Chickering JG; Chien YT; Carlson K; Cressman MD; Currie MG; Milne GT; Profy AT
Clin J Am Soc Nephrol; 2020 Dec; 16(1):59-69. PubMed ID: 33328269
[TBL] [Abstract][Full Text] [Related]
10. Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial.
Greeviroj P; Puapatanakul P; Phannajit J; Takkavatakarn K; Kittanamongkolchai W; Boonchaya-Anant P; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Clin Nephrol; 2023 Nov; 100(5):224-230. PubMed ID: 37675488
[TBL] [Abstract][Full Text] [Related]
11. A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial.
Bakris GL; Mikami H; Hirata M; Nakajima A; Cressman MD
Kidney360; 2021 Aug; 2(8):1240-1250. PubMed ID: 35369650
[TBL] [Abstract][Full Text] [Related]
12. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
de Zeeuw D; Bekker P; Henkel E; Hasslacher C; Gouni-Berthold I; Mehling H; Potarca A; Tesar V; Heerspink HJ; Schall TJ;
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):687-96. PubMed ID: 26268910
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.
Nangaku M; Takama H; Ichikawa T; Mukai K; Kojima M; Suzuki Y; Watada H; Wada T; Ueki K; Narita I; Kashihara N; Kadowaki T; Hase H; Akizawa T
Nephrol Dial Transplant; 2023 May; 38(5):1204-1216. PubMed ID: 36002026
[TBL] [Abstract][Full Text] [Related]
14. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
[TBL] [Abstract][Full Text] [Related]
15. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
[TBL] [Abstract][Full Text] [Related]
17. Chymase inhibition retards albuminuria in type 2 diabetes.
Bivona BJ; Takai S; Seth DM; Satou R; Harrison-Bernard LM
Physiol Rep; 2019 Dec; 7(24):e14302. PubMed ID: 31872559
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Andress DL; Coll B; Pritchett Y; Brennan J; Molitch M; Kohan DE
Life Sci; 2012 Oct; 91(13-14):739-42. PubMed ID: 22326504
[TBL] [Abstract][Full Text] [Related]
19. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
20. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
Tan SMQ; Chiew Y; Ahmad B; Kadir KA
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
